- Home
- ITRM vs INKT Comparison
ITRM vs INKT Comparison
Compare ITRM & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ITRM
- INKT
- Stock Information
- Founded
- ITRM 2015
- INKT 2017
- Country
- ITRM Ireland
- INKT United States
- Employees
- ITRM N/A
- INKT N/A
- Industry
- ITRM Biotechnology: Pharmaceutical Preparations
- INKT Medicinal Chemicals and Botanical Products
- Sector
- ITRM Health Care
- INKT Health Care
- Exchange
- ITRM Nasdaq
- INKT Nasdaq
- Market Cap
- ITRM 24.7M
- INKT 28.5M
- IPO Year
- ITRM 2018
- INKT 2021
- Fundamental
- Price
- ITRM $1.37
- INKT $0.75
- Analyst Decision
- ITRM Strong Buy
- INKT Strong Buy
- Analyst Count
- ITRM 1
- INKT 2
- Target Price
- ITRM $5.00
- INKT $6.50
- AVG Volume (30 Days)
- ITRM 7.1M
- INKT 32.0K
- Earning Date
- ITRM 11-14-2024
- INKT 11-14-2024
- Dividend Yield
- ITRM N/A
- INKT N/A
- EPS Growth
- ITRM N/A
- INKT N/A
- EPS
- ITRM N/A
- INKT N/A
- Revenue
- ITRM N/A
- INKT N/A
- Revenue This Year
- ITRM N/A
- INKT N/A
- Revenue Next Year
- ITRM N/A
- INKT N/A
- P/E Ratio
- ITRM N/A
- INKT N/A
- Revenue Growth
- ITRM N/A
- INKT N/A
- 52 Week Low
- ITRM $0.81
- INKT $0.57
- 52 Week High
- ITRM $2.50
- INKT $1.90
- Technical
- Relative Strength Index (RSI)
- ITRM 54.25
- INKT 54.46
- Support Level
- ITRM $1.25
- INKT $0.74
- Resistance Level
- ITRM $1.61
- INKT $0.80
- Average True Range (ATR)
- ITRM 0.14
- INKT 0.05
- MACD
- ITRM 0.00
- INKT 0.01
- Stochastic Oscillator
- ITRM 46.67
- INKT 62.60
About ITRM Iterum Therapeutics plc
Iterum Therapeutics PLC is a clinical-stage pharmaceutical company. The company is engaged in developing and commercializing sulopenem to be the first and only oral and intravenous branded penem available globally. Its sulopenem program has the potential to offer a solution to the problem of antibiotic resistance and the toxicity limitations of existing agents. The company operates as a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing allogeneic invariant natural killer T-cell therapies to treat cancer and other life-threatening illnesses.